Diphenylpyraline
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Diphenylpyraline: From First-Generation Antihistamine to Allergic Urticaria
One-Sentence Summary
Diphenylpyraline is a first-generation H1 receptor antagonist (antihistamine) with no currently registered indications in South Africa. The TxGNN model predicts it may be effective for Allergic Urticaria with a score of 99.61%, however there are currently no clinical trials and no published literature specifically supporting this drug-indication pairing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registered indication (not marketed in South Africa) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Diphenylpyraline is a first-generation H1 receptor antagonist belonging to the diphenylmethane/piperidine class of antihistamines. Although detailed pharmacological mechanism data is not currently available in the evidence pack, Diphenylpyraline acts by competitively blocking histamine at the H1 receptor, thereby inhibiting the downstream effects of histamine release from mast cells and basophils — including vasodilation, increased vascular permeability, pruritus, and wheal-and-flare reactions characteristic of urticaria.
The mechanistic link between Diphenylpyraline and allergic urticaria is strong in principle. Allergic urticaria is driven precisely by IgE-mediated mast cell degranulation and histamine release, making H1 receptor antagonism the cornerstone of its pharmacological management. Current international guidelines (EAACI/GA²LEN/EDF/WAO) consistently recommend H1 antihistamines as first-line therapy for urticaria. Diphenylpyraline shares this mechanism with all approved antihistamines for this indication, representing a clear class-effect rationale.
However, a critical limitation must be noted: current clinical guidelines favour second-generation antihistamines (e.g., cetirizine, loratadine, fexofenadine) over first-generation agents for urticaria due to their superior tolerability profile (reduced sedation, anticholinergic effects). Diphenylpyraline, as a first-generation agent, would face significant competitive disadvantage unless a specific clinical or formulation advantage can be demonstrated. The TxGNN prediction reflects biological plausibility rather than clinical novelty.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available specifically for Diphenylpyraline in allergic urticaria.
Note: Although no literature was identified for the top-ranked indication (allergic urticaria), 4 historical publications were identified for the related indication rhinitis (rank 7 in predictions). These are summarised below for contextual reference, as they provide the only direct clinical evidence for Diphenylpyraline in allergic conditions.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14039 | 1977 | Non-randomised Clinical Study | J Int Med Res | Double-blind study (n=63 active, n=57 placebo); Diphenylpyraline (Lergobine) showed statistically significant improvement in mucus discharge and eye redness vs placebo in allergic and vasomotor rhinitis patients |
| 13294977 | 1956 | Early Clinical Trial / Case Series | The Journal of Allergy | Early clinical evaluation of Diphenylpyraline as an antihistamine agent |
| 13125198 | 1954 | Early Clinical Trial | Annals of Allergy | Clinical evaluation of Diphenylpyraline specifically in ragweed pollinosis (hay fever) |
| 13683344 | 1961 | Clinical Study | Svenska Läkartidningen | Diphenylpyraline HCl (Histyn) in long-acting preparations (Durettes) evaluated in hay fever patients |
South Africa Market Information
Diphenylpyraline is not currently registered with SAHPRA and has no active product licences in South Africa. There are no registered products to list.
This drug is not on the South African Essential Medicines List (EML). Any introduction would require a new marketing authorisation application to SAHPRA before clinical use.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. As Diphenylpyraline is not currently registered in South Africa, clinicians should consult the prescribing information from a jurisdiction where the drug is registered (e.g., UK, Japan). Report any adverse drug reactions to SAHPRA via the MedSafety reporting system.
General class considerations for first-generation antihistamines (applicable pending full PI review): Central nervous system depression (sedation, drowsiness), anticholinergic effects (dry mouth, urinary retention, blurred vision, constipation), and impaired cognitive/psychomotor performance are well-established class effects. Use with caution in elderly patients, those operating machinery, and patients with prostatic hypertrophy or narrow-angle glaucoma.
Conclusion and Next Steps
Decision: Hold
Rationale: While the mechanistic rationale for Diphenylpyraline in allergic urticaria is biologically sound (H1 antagonism is the established treatment mechanism), the drug has no SAHPRA registration, no clinical trials, and no published literature specifically for this indication. The prediction score of 99.61% reflects class-effect plausibility rather than drug-specific evidence, and first-generation antihistamines are not recommended as preferred agents in current urticaria guidelines.
To proceed, the following is needed:
- Regulatory data: Obtain full prescribing information / Professional Information (PI) from a jurisdiction where Diphenylpyraline is registered to assess safety warnings and contraindications
- Mechanism of action data: Retrieve complete pharmacological profile from DrugBank (DB01146) including receptor binding data and pharmacokinetic parameters
- Differentiation analysis: Identify any pharmacokinetic, formulation, or patient-population advantage that would distinguish Diphenylpyraline from currently preferred second-generation antihistamines in urticaria management
- Literature search expansion: Conduct a broader PubMed search (not limited to allergic urticaria) to capture historical data on Diphenylpyraline’s use in urticaria-related conditions and atopic diseases
- Regulatory pathway assessment: Determine SAHPRA registration requirements and timeline for a new marketing authorisation application
- Clinical context review: Consult South African Allergy Society guidelines to determine whether a first-generation antihistamine can address any unmet clinical need in the local context (e.g., cost, availability of alternatives)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.